Těžké astma

Postery prezentované na AAAAI Annual Meeting, San Francisco, CA, USA, 22.–25. února, 2019

• • Clinically meaningful improvements in asthma control questionnaire (ACQ) scores occur early, while asthma-related quality of life (AQLQ) scores continue to improve over 52 weeks, among patients with eosinophilic asthma receiving IV reslizumab (staženo 38× )

 

• • High peripheral blood eosinophil levels are associated with low FEV1 reversibility in patients with severe eosinophilic asthma (staženo 40× )

 

• • Evaluation of eosinophilic asthma patients without blood eosinophil (EOS) response to intravenous (IV) reslizumab in a post-hoc analysis of 52-week placebo-controlled Phase 3 studies (staženo 38× )

 

• • A high proportion of exacerbation-prone patients with uncontrolled eosinophilic asthma receiving intravenous (IV) reslizumab experienced zero asthma exacerbations through 52 weeks of treatment (staženo 36× )

 

• • Variability in absolute blood eosinophil (EOS) counts over 52 weeks in patients with inadequately controlled eosinophilic asthma receiving placebo in two duplicate clinical trials (staženo 40× )

 

Odborné texty

• • Secondary loss of response to mepolizumab in severe eosinophilic asthma (staženo 32× )

 

• • Novosad J, Krčmová I. Reslizumab. Remedia 2/2019 (staženo 91× )

 

• • Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab (staženo 74× )

 

• • Reslizumab v terapii pacientů s nedostatečně kontrolovaným eozinofilním astmatem (staženo 264× )

 

Prezentace

• Jak přistupovat k léčbě obézních pacientů s těžkým astmatem
  Milan Teřl

• Reslizumab v terapii neatopického eosinofilního astmatu
  Alena Vlachová

• Přínos reslizumabu pro astmatiky s chronickou rinosinusitidou a nazálními polypy
  Irena Krčmová